title: Measuring prostate-specific quality of life in prostate cancer patients scheduled for radiotherapy or radical prostatectomy and reference men in Germany and Canada using the Patient Oriented Prostate Utility Scale-Psychometric (PORPUS-P).
abstract: BACKGROUND
  The PORPUS-P is a short questionnaire for measuring prostate-specific quality of life (QoL), which was designed in Canada for use in prostate cancer (PC) patients. We aimed to generate a German version and compare PORPUS-P scores of German reference men from the general population, and German and Canadian patients with newly diagnosed PC who were scheduled to receive radical prostatectomy (RP) or radiotherapy (RT).
  
  
  METHODS
  The study sample consisted of 988 reference men, 121 German and 66 Canadian PC patients scheduled for RT, and 371 German and 68 Canadian PC patients scheduled for RP. All men completed the PORPUS-P (German postal questionnaire, Canada personal interview). Data were gathered from PC patients before the start of therapy.
  
  
  RESULTS
  Canadian patients were better educated than the German patients, and fewer were retired. Patients scheduled to receive RT were older and more were retired. German RT patients had lower D'Amico risk scores and pre-treatment Gleason scores than RP patients, and Canadian RT patients had higher pre-treatment PSA than RP patients. Urinary and sexual dysfunction were seen in PC patients (especially RT patients), but were also common in the German reference men. Crude mean PORPUS-P scores differed statistically significant between German RT and RP and Canadian RP and RT patients, with RT patients having higher QoL scores. The differences in age-adjusted mean PORPUS-P scores between reference men and RP patients were not clinically significant, while RT patients had (clinically) significantly lower scores than the reference men.
  
  
  CONCLUSIONS
  The German translation of the PORPUS-P appears to be a short and feasible tool for assessing prostate-specific QoL. Although we found a similar response pattern, Canadian and German PC patients scheduled to receive RT or RP rated their pre-treatment quality of life on different levels, which reveals the need for national reference data. Problems in several QoL domains exist before treatment, and differ between PC patients scheduled for RT and RP.
authors.affiliation: Institute of Cancer Epidemiology, University Luebeck, Beckergrube 43-47, 23552 Luebeck, Germany. Annika.Waldmann@krebsregister-sh.de
authors.forename: Annika
authors.initials: A
authors.lastname: Waldmann
authors.forename: Volker
authors.initials: V
authors.lastname: Rohde
authors.forename: Karen
authors.initials: K
authors.lastname: Bremner
authors.forename: Murray
authors.initials: M
authors.lastname: Krahn
authors.forename: Thomas
authors.initials: T
authors.lastname: Kuechler
authors.forename: Alexander
authors.initials: A
authors.lastname: Katalinic
mesh_terms: D000368:Aged; D002170:Canada; D003131:Combined Modality Therapy; D005858:Germany; D006801:Humans; D008297:Male; D008875:Middle Aged; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000523:psychology* / Q000532:radiotherapy* / Q000601:surgery; D011594:Psychometrics; D011788:Quality of Life; D011795:Surveys and Questionnaires; D014175:Translating; D016896:Treatment Outcome; D044465:White People / Q000523:psychology
references.citation: Int J Cancer. 2005 Aug 20;116(2):291-6
references.pmid: 15800919
references.citation: Qual Life Res. 2007 Dec;16(10):1665-75
references.pmid: 17912614
references.citation: Eur J Cancer. 2008 Mar;44(4):572-8
references.pmid: 18221866
references.citation: Neurourol Urodyn. 2000;19(3):259-71
references.pmid: 10797583
references.citation: Qual Life Res. 1996 Dec;5(6):555-67
references.pmid: 8993101
references.citation: Cancer. 2007 Jul 1;110(1):196-202
references.pmid: 17546575
references.citation: J Clin Oncol. 1998 Jan;16(1):139-44
references.pmid: 9440735
references.citation: Cancer. 2007 Jun 1;109(11):2239-47
references.pmid: 17455209
references.citation: J Clin Epidemiol. 2005 May;58(5):466-74
references.pmid: 15845333
references.citation: Eur J Cancer. 2001 Jul;37(11):1345-51
references.pmid: 11435063
references.citation: Asian J Androl. 2009 May;11(3):283-90
references.pmid: 19349948
references.citation: Qual Life Res. 2007 Apr;16(3):509-22
references.pmid: 17091359
references.citation: Cancer. 2003 Dec 1;98(11):2335-43
references.pmid: 14635067
references.citation: J Chronic Dis. 1987;40(5):373-83
references.pmid: 3558716
references.citation: J Urol. 2008 Apr;179(4):1354-60; discussion 1360-1
references.pmid: 18289596
references.citation: J Sex Med. 2008 Apr;5(4):919-927
references.pmid: 18371045
references.citation: Urol Res. 2004 Aug;32(4):283-9
references.pmid: 15057494
references.citation: Radiat Oncol Investig. 1999;7(3):178-85
references.pmid: 10406060
references.citation: JAMA. 1993 Jul 7;270(1):83-90
references.pmid: 8510302
references.citation: Urology. 1999 Sep;54(3):509-16
references.pmid: 10475363
references.citation: Int J Impot Res. 2007 Mar-Apr;19(2):183-8
references.pmid: 16885992
references.citation: J Clin Epidemiol. 2000 Sep;53(9):920-30
references.pmid: 11004418
references.citation: J Urol. 2005 Dec;174(6):2105-10
references.pmid: 16280737
references.citation: J R Soc Med. 2003 Sep;96(9):442-8
references.pmid: 12949200
references.citation: J Urol. 2006 Dec;176(6 Pt 1):2443-7
references.pmid: 17085125
references.citation: Prostate Cancer Prostatic Dis. 2007;10(1):52-9
references.pmid: 17102801